Disease relevance of Rociverine

• Rociverine for nocturia in the elderly [1].
• Considering the efficacy of rociverine and, even more important, the excellent tolerance of elderly patients to the drug, further study of rociverine in nocturia and in urinary incontinence seems indicated [1].
• Forty inpatient men and women, between 50 and 80 years of age, with nocturia due to bladder instability, resorption of postural edema, or senile involution were admitted to a clinical trial designed to test the possibility of reducing or eliminating nocturnal voidings by means of a single evening dose of rociverine or flavoxate [1].
• Orally administered rociverine produced a dose-related reversal of the reserpine-induced detrusor hyperreflexia in anaesthetized rats [2].
• It is suggested, therefore, that rociverine may be administered, if necessary, even to patients with angle-closure glaucoma [3].

High impact information on Rociverine

• Effect of rociverine on P450-dependent monooxygenases and its N-deethylation metabolism in rat liver microsomes [4].
• Verapamil and rociverine, but not the other drugs mentioned above, were also active on ileum [5].
• Effectlessness of a new spasmolytic (rociverine) on intraocular pressure, pupil size, and iridocorneal angle in ophthalmically healthy subjects [6].
• The use of rociverine as premedication for endoscopy of the upper gastro-intestinal tract: a double-blind controlled clinical trial [7].
• On the contrary, rociverine displayed a dual effect being a competitive antagonist at low (up to 10(-5) mol/l) and a mixed one at high (greater than 10(-5) mol/l) concentrations [8].

Biological context of Rociverine

• Effects of rociverine and other spasmolytic agents on caerulein-induced delay in gastric emptying in the conscious rat [9].

Anatomical context of Rociverine

• Mechanism of smooth muscle relaxation by rociverine [10].
• Effects of rociverine on the human ureter: in vivo and in vitro experimental study [11].
• Against calcium in the same preparations rociverine behaves as a competitive antagonist with 10 times less potency than verapamil on the vas deferens and 300 times less on the aorta [10].
• The muscle-relaxant activity of rociverine is achieved by inhibiting the availability of Ca2+ at contraction site and not through an antiphosphodiesterasic mechanism, which might explain the absence of muscle-relaxant effects on the smooth musculature of the blood vessels [12].
• Antispasmodic activity of rociverine on the smooth musculature of the urinary tract. Comparative in vitro study [13].

Associations of Rociverine with other chemical compounds

• In sum, the smooth-muscle relaxant action of rociverine depends on a modest antimuscarinic action and a direct myolytic action, the latter probably being due to an inhibitory action on the transmembrane fluxes of Ca2+ [10].
• Both on rat vas deferens and on rabbit aorta rociverine at low doses slightly potentiates the response to norepinephrine (unrelated to any inhibition of uptakes), whereas at higher doses it depresses the maximum effect, 10 times more on the vas deferens than on the aorta [10].
• In vitro (human ureter strips), rociverine exerted a spasmolytic activity both on the baseline motility and on the spasm induced by direct contractants (eledoisin, KCl) or by histamine [11].
• The ability of the antispasmodic drugs atropine, N-butylscopolamine, papaverine, trimebutine, dicyclomine, and rociverine to delay gallbladder emptying was determined by administering them either intraperitoneally or orally 7.5 or 15 min prior to egg yolk [14].

Analytical, diagnostic and therapeutic context of Rociverine

• Thirty-seven subjects without eye diseases were treated with rociverine, a new direct myolytic and parasympatholytic antispasmodic: 15 by intravenous injection (20 mg) and 22 by oral administration (20 mg three times daily for four days) [6].

References